Loading
StemCell Institute Inc.: what insiders have been doing
Insider filings for StemCell Institute Inc. are scarce in the EDINET (Japan FSA) feed, the latest one published on 3 March 2025. This page will fill in as new trades are disclosed. Every figure here comes from the filings published by EDINET (Japan FSA) and describes the past, not future prices; it is not investment advice.
Insider Decl.
1
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Fundamental score
Ranked 14,542 of 23,476 companies
44.2
score / 100
Value29
Quality60
FCF yld-6.0%
Earn yld2.1%
EV/EBITDA21.3x
ROE4.6%
Gross mgn61%
Net mgn5.5%
Debt/EBITDA1.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended March 2026 · cache
JP¥755
Analyst consensus
Income statement
RevenueJP¥2.8B
Gross profitJP¥1.7B61% margin
EBITDAJP¥380M14% margin
Net incomeJP¥155.9M5.5% margin
Valuation
PER (trailing)49.1x
P/Book2.8x
Beta0.64
Balance sheet & cash
Market capJP¥7.6B
Total debtJP¥473.8M
Free Cash Flow-JP¥453.3M
Debt / Equity19%
Profitability & ownership
ROE4.6%
ROA1.6%
% insiders75.6%
% institutions0.5%
Last declaration on 3 March 2025
About StemCell Institute Inc.
株式会社ステムセル研究所 is a Japanese company focused on the research and development of stem cell-based therapies. It is listed on the XTKS market.